Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Journal of the American College of Cardiology

Volumn 35, Issue 5, 2000, Pages 1103-1115

  Lincoff, A Michael ^a   Califf, Robert M ^b   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; PLACEBO; TIROFIBAN; VON WILLEBRAND FACTOR;

BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS LINKING; DEATH; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HEPARINIZATION; HUMAN; LIGAND BINDING; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PLASMA HALF LIFE; PRIORITY JOURNAL; RECEPTOR BLOCKING; REOPERATION; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA;

EID: 0034127259     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00554-4     Document Type: Article

References (58)

1. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (part I). N Engl J Med. 326:1992;242-250.
2. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (part II). N Engl J Med. 326:1992;310-318.
3. Steele P.M., Chesebro J.H., Stanson A.W., et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circulation Res. 57:1985;105-112.
4. Uchida Y., Hasegawa K., Kawamura K., Shibuya I. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J. 117:1989;769-776.
5. Lewis H.D.J., Davis J.W., Archibald D.G., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina results of the Veterans Administration Cooperative Study . N Engl J Med. 309:1983;396-403.
6. Cairns J.A., Gent M., Singer J., et al. Aspirin, sulfinpyrazone or both in unstable angina. N Engl J Med. 313:1985;1369-1375.
7. Theroux P., Ouimet H., McCans J., et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
8. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 336:1990;827-830.
9. Schwartz L., Bourassa M.G., Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 318:1988;1714-1719.
10. Collaborative overview of randomized trials of antiplatelet therapy-I prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients . Br Med J. 308:1994;81-106.
11. Phillips D.R., Charo I.F., Parise L.V., Fitzgerald L.A. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 71:1988;831-843.
12. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559.
13. Coller B.S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 92:1995;2373-2380.
14. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
15. Kleiman N.S., Raizner A.E., Jordan R., et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab implications for inhibition of the internal pool of GPIIb/IIIa receptors . J Am Coll Cardiol. 26:1995;1665-1671.
16. Mascelli M.A., Lance E.T., Damaraju L., Wagner C.L., Weisman H.F., Jordan R.E. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation. 97:1998;1680-1688.
17. Harrington R.A., Kleiman N.S., Kottke-Marchant K., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 76:1995;1222-1227.
18. Kereiakes D.J., Kleiman N.S., Ambrose J., et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
19. Alig L., Edenhofer A., Hadvary P., et al. Low molecular weight, nonpeptide fibrinogen receptor antagonists. J Med Chem. 35:1992;4393-4407.
20. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
21. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
22. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet. 352:1998;87-92.
23. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT II . Lancet. 349:1997;1422-1428.
24. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
25. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
26. Brener S.J., Barr L.A., Burchenal J.E.B., et al. A randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 98:1998;734-741.
27. Gibson C.M., Goel M., Cohen D.J., et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol. 32:1998;28-34.
28. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 334:1996;1084-1089.
29. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. N Engl J Med. 339:1998;1665-1671.
30. Lincoff A.M., Tcheng J.E., Califf R.M., et al. Standard versus low dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. Am J Cardiol. 79:1997;286-291.
31. Ghaffari S., Kereiakes D.J., Lincoff A.M., et al. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. Am J Cardiol. 82:1998;7-12.
32. Lincoff A.M., Califf R.M., Anderson K.M., et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by c7E3 Fab (abciximab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol. 30:1997;149-156.
33. Topol E.J., Califf R.M., Weisman H.S., et al. Reduction of clinical restenosis following coronary intervention with early administration of platelet IIb/IIIa integrin blocking antibody. Lancet. 343:1994;881-886.
34. Topol E.J., Ferguson J.J., Weisman H.F., et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. JAMA. 278:1997;479-484.
35. Lincoff A.M., Tcheng J.E., Califf R.M., et al. Sustained supression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab 1 year outcome in the EPILOG trial . Circulation. 99:1999;1951-1958.
36. Lincoff A.M., Califf R.M., Moliterno D.J., et al. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. New Engl J Med. 341:1999;319-327.
37. Topol E.J., Mark D.B., Lincoff A.M., et al. Enhanced survival with platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting 1 year outcomes and health care economic implications from a multicenter, randomized trial . Lancet. 354:1999;2019-2024.
38. Carrozza J.P., Kuntz R.E., Fishman R.F., Baim D.S. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Int Med. 118:1993;344-349.
39. Blankenship J.C., Menapace F.J., Demko S.L. Incidence of intracranial hemorrhage in trials of glycoprotein IIb/IIIa receptor inhibitor drugs. (abstr) J Am Coll Cardiol. 33:1999;41A.
40. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339:1998;436-443.
41. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med. 338:1998;1488-1497.
42. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 338:1998;1498-1505.
43. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor, heparin or both in unstable angina. Circulation. 97:1998;2386-2395.
44. Harrington R.A., Lincoff A.M., Berdan L.G., et al. Maintenance of clinical benefit at 6 months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. (abstr) Circulation. 98:1998;I359.
45. Van de Werf F., Topol E.J., Lee K.L., et al. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. JAMA. 273:1995;1586-1591.
46. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 98:1996;863-874.
47. 2+ on GP IIb-IIIa interactions with integrilin. Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 96:1997;1488-1494.
48. Juergens C.P., Yeung A.C., Oesterle S.N. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol. 80:1997;74-75.
49. Boehrer J.D., Kereikes D.J., Navetta F.I., Califf R.M., Topol E.J. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol. 74:1994;1166-1170.
50. Booth J., Patel V., Balog C., et al. Is bleeding risk increased in patients undergoing urgent bypass surgery following abciximab. (abstr) Circulation. 98:1998;I845.
51. Tcheng J.E., Kereiakes D.J., Braden G.A., et al. Safety of abciximab retreatment - final clinical report of the ReoPro Readministration Registry (R3). (abstr) Circulation. 98:1998;I17.
52. Popma J.J., Weitz J., Bittl J.A., et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest. 114:1998;7288-7418.
53. Garbarz E., Farah B., Vuillemenot A., et al. "Rescue" abciximab for complicated percutaneous transluminal coronary angioplasty. Am J Cardiol. 82:1998;800-803.
54. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical Practice Guideline Number 10. AHCPR Publication No. 94-0602. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung and Blood Institute, Public Health Service, U.S. Department of Health and Human Services, 1994.
55. Ohman E.M., Armstrong P.W., Christenson R.H., et al. Cardiac troponin T levels for risk stratificcation in acute myocardial ischemia. N Engl J Med. 335:1996;1333-1341.
56. Oler A., Whooley M.A., Oler J., Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina a meta-analysis . JAMA. 2276:1996;811-815.
57. Rao A.K., Pratt C., Berke A., et al. Thrombolysis in myocardial infarction (TIMI) trial - phase I hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase . J Am Coll Cardiol. 11:1988;1-11.
58. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation. 82:1990;1193-1202.